Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by lv_426on Nov 21, 2019 1:35am
65 Views
Post# 30376998

RE:The near term news we can expect

RE:The near term news we can expect
Inv3strr wrote: We don't know what repilcel has been up to until they tell us in a news release, but I think it will include:

- Dermal injector prototype is done. So... What's it look like?. How does it function? What can it do? How will it change our lives? Maybe some experts talking about it. Trade shows? Soon we will have more than just 1 or 2 pictures ... maybe a  big marketing campaign coming up if they actually want to commercialize next year. 

-Dermal injector updates about the manufacturing setup and how many they will make for first launch

- Dermal injector and yofoto and what's the plan there. ... 

- Dermal injector data about expected market size in Europe and HK.. whats the expected revenue from that..

- Shiseido update about what's happening.... now that there's the patent replicel should want the data so they should tell us the plan. Wait it out?  Ask shiseido? Maybe shiseido needs the replicel  injector. That would be the best news ever.

- Clinical phase 2 studies on tendon and skin in china and HK and japan. 

- partnerships in japan

- UBC and UVIC study results which i think is happening right now

That's all just off the top of my head.... There's a lot happening, and these are some of the near term things we might see in coming updates.  Like before December probably. So don't panic there will be a  lot of good news to chew on. 




I admire your endless positivity but where is the money coming from to found this? Based on your logic both Shiseido and YOFOTO will be participating in this lasting financing, because they dont want replicel to fail. Actually the tranche should over subscribed.....
Bullboard Posts